{"name":"Affibody","slug":"affibody","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ABY-035 i.v.","genericName":"ABY-035 i.v.","slug":"aby-035-i-v","indication":"Other","status":"phase_1"},{"name":"ABY-035 s.c.","genericName":"ABY-035 s.c.","slug":"aby-035-s-c","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ABY-035 i.v.","genericName":"ABY-035 i.v.","slug":"aby-035-i-v","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABY-035 s.c.","genericName":"ABY-035 s.c.","slug":"aby-035-s-c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOSUtBeTVrV244MDBBX3NDdnVyaVJ5OS1IYWtkWEZNRmJRMnBiR2VreVctZmUyeWxvSHRJTUFLTUw2a09RYzJLR281NHl3a0tUSUJvZk42LTBLb1BmODFyMV9PM3B1T3RNTFVDaEJ3cHA5Z1JpcHRUMzdjSlJCbXhXWjFkWjBCMEFPdWlJQ0xiWkM4LUUwZ1R2aENSeU9ic2ZVSm54MzY5bVRMeTI0WFVjMXpZVEdNaklqZy1fX1hHc3hXd255V1lrQ2RfdmxVSlR2TDR3eGt4V3lFZHRoOTI0RmQtMWVxMEc1R21qNjgxdnhMZGpQWXBOcmVvVG1jR2pwLU5QSUNpbUdoWTNMajFfOG9XdXpoOFFJSkZkOHZpeGVoQWo5eXRYRVd1cnFvWDhjSlcwX2VTUFJBOWlSRlhwZ1ZNV3I?oc=5","date":"2025-07-21","type":"pipeline","source":"prnewswire.com","summary":"Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight - prnewswire.com","headline":"Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Ind","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPWXBLMWZuUUF2ZGd1N0hPTmJKbHFKc3RrdzRXbDY5ZGpMZWkyRl9keDhBSktEeXgzQ0FadVdpeWZoNEhHc3lINE8wTnJWYUs1dlpVdzB4Z044T2o2eGRLS0ZzTGJBZUxlWU9VQ3J4Q0RXSHlvaU5NcU1Vc0ZnWjBrUlh6X1RBdjE2SWY4U0RlZTRqSHdBLTd1NXgtSXVFVGh4VnA4Ni1TWTJ3bXBHczFLQzVneTlCMDk0bTJmdXBJaw?oc=5","date":"2025-02-03","type":"deal","source":"fiercebiotech.com","summary":"Affibody regains autoimmune asset, claims ex-partner Acelyrin unable 'to fully capitalize' on potential - fiercebiotech.com","headline":"Affibody regains autoimmune asset, claims ex-partner Acelyrin unable 'to fully capitalize' on potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5KWUQzS2ZsSXF6dHVBYW5Fa2tPWHVFaTgzX3NVSzNvMTlmNkVJVHRBY21jSlYtRm5qVGdBU0g1OFoyTmJyVUdfRWlXOXdMNkRpWnI0TmNObUJSZGl6Y2NJ?oc=5","date":"2025-01-02","type":"pipeline","source":"Nature","summary":"DGCR2 targeting affibody molecules for delivery of drugs and imaging reagents to human beta cells - Nature","headline":"DGCR2 targeting affibody molecules for delivery of drugs and imaging reagents to human beta cells","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNbFhKXzZaUFVoX2Nfb1BiMGZlSEFKbXpMTTVMdXFaVDk2LXIwZVV6dVFGUVZUN1JrVlhHNmI1bUx5YmwwMkw5c3ZVcDVIbVZpby1UREhmSGpFYzctcDZpeDN0bGdLdllVSTg3Q21ZdUtMTUdiN0FYUTRkdFRqS1RyQzNETmd3VkhPSHNIVTJzSmhDaWdIM2JYSkphM1g2VWtmNk54TmVzc0Y0VFY2a1hGSHQzRnJ3cEVnOU9PNi0wdlAxZUxL?oc=5","date":"2023-03-07","type":"deal","source":"fiercebiotech.com","summary":"Chiesi offers Affibody breath of fresh air in respiratory disease deal worth up to $637M - fiercebiotech.com","headline":"Chiesi offers Affibody breath of fresh air in respiratory disease deal worth up to $637M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNbEhCMGExWFd0VkNPeVkwRWJkREdINC1wYVBuOUJhdkZRWV9aSW9abl9UT05TUWJfdzhMTDFuMUJMR29JTEVXb2toSU81cjJSaVFfaFRGbE5MZm92ZmczWjd5aXFpRlItM3dtMUJMZF9wejljbkxPOGdtRTNGZEt3aXVlMzRPS0tZbHpyQkxMY3JoSGdTaF9LSVNLMDRmTVFQdGJYM29xV0lsNDVXMGw5SGRfRGZlZ0E?oc=5","date":"2022-09-14","type":"regulatory","source":"Labiotech.eu","summary":"Treatment for adults with moderate to severe psoriasis approved by FDA - Labiotech.eu","headline":"Treatment for adults with moderate to severe psoriasis approved by FDA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNbXVNdGxoNzBJX1R2NTBNR083WTlUbXRTMVJ2M2FBQzRSNXpWVGdqUndQWTVDME1KRzR5ZEJjcy1DX01lc3E3NW5BMGJZWUYwbWNkcVlOdUM3UHFjWlFhTzV0MHgwdmxOakcwMmpVcHBVb1YtWXZscVgtenN3WHBNREVfRjdzanBsNFZGLUhrTkllTmItVWVTaFM0WDRoLUs4TnZyMGRKUG1waUxRRVJ6LTVB?oc=5","date":"2019-11-26","type":"pipeline","source":"European Medical Journal","summary":"Epithelial Barrier Dysfunction in Type 2 Inflammatory Diseases - European Medical Journal","headline":"Epithelial Barrier Dysfunction in Type 2 Inflammatory Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9tenkxSGlUcUFzZDJ3WWtsaU9RWEEzd1ZJbl9vc09pSTNDTVY2ZDRKdE8tY3Vab3V1eU5acHJvLThFOWljZEtaVGlpUkxJd3VWUVRCVDlUYjhDMmktelAw?oc=5","date":"2019-10-17","type":"pipeline","source":"Nature","summary":"Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts - Nature","headline":"Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNQ1l4N09RNFF3TzJIb2pKdWsxdkZxWkxsaEFoc1I0Z3llVnFWUUZpemtaRDg0eHpHTzR2Uk5iN3BBc3o5NHl4eWhmYmF2YUt5cUhxcDVSMlNRbmRHSGpVQ2hGcG5nMl84a0U5a0ctUW40akZkN3pRVloxVlBDd1k3RkduQV9SX1BMUTduNWctTHEzRDltX3NSblVocw?oc=5","date":"2019-03-20","type":"deal","source":"BioPharma Dive","summary":"Alexion adds to pipeline with 2 early-stage R&D deals - BioPharma Dive","headline":"Alexion adds to pipeline with 2 early-stage R&D deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNMU9ZcjlMdEkwdGtZWWM2NDZaX3FGMDg2MER4eUVNZUtzanpncjhXQjNTd2JDTThqQ3JxdjRoSjFHekN5SVplcjJrdlN1V3VEdWdoZjUzM204YTNQQXZpbTI2WXNic0NhTEctalRVaGwwUnhNNHk5N29MaWJyc0tUMHZiU3A2OWpkTEFNYndpMFA3TVgwTUVvbzh0cnk5a3F1WUZRNWduWjJFOE9MM3dkV045Zw?oc=5","date":"2019-03-20","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Alexion Inks Collaborations Totaling $1.3B+ with Affibody, Zealand - Genetic Engineering and Biotechnology News","headline":"Alexion Inks Collaborations Totaling $1.3B+ with Affibody, Zealand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQVzVTTFlMVEt6Y1JtRVMxVmphVVZla20tSVBLOG1oT05NQUtfazJCbGUzdVlHcExyU1Z3c2xSNWdhcFpCY2QybEdXaHZPVk5jSHZZWENmaXVIQ1BLODFRbmtZZk8td2t6bGlJVTNFVmtNc0JlYmxodFRMOE1Pa0N6TlJtczlWTHB5VzNQNXpCamlIbW9KbjFHWEt2d0Izd0k?oc=5","date":"2019-03-20","type":"deal","source":"fiercebiotech.com","summary":"Alexion strikes another anti-FcRn deal, bagging Affibody drug - fiercebiotech.com","headline":"Alexion strikes another anti-FcRn deal, bagging Affibody drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBNcVplckQzRTUxX0NkNkc2a3Z4alJvR0VuQjIyWmdiR0JaSXZybzZHSFREZ3ZGUWVkNlpPTm14Xzl4UnQ4U1FUQnR1c1dHNzhJelBJSXlWWUM3eFhQaDVJ?oc=5","date":"2017-07-20","type":"regulatory","source":"Nature","summary":"The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule - Nature","headline":"The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1fYWRSQTZPOFhOQ3BUMi1ia1lGbThjZWEtWW1VZ0U3LUN4bHk4YWRpTVhNWkwtdHUyaEVxQm1hQVF4Zkd1TTlIVWh4Q0RLTm9GOWdr?oc=5","date":"2015-10-19","type":"pipeline","source":"Nature","summary":"Affibody-mediated PET imaging of HER3 expression in malignant tumours - Nature","headline":"Affibody-mediated PET imaging of HER3 expression in malignant tumours","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}